



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No.

10/509,256

**Applicant** 

LANKINEN et al.

Filed

June 14, 2005

TC/A.U.

1614

Examiner

Unassigned

Docket No.

1300-142

Customer No.

06449

Confirmation No.

1261

## **INFORMATION DISCLOSURE STATEMENT**

Director of the United States Patent and Trademark Office P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Under the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicant submits herewith information that the Office may wish to consider in examination of the subject application. The publications are listed on the attached form PTO-1449.

FI105074 corresponds to U.S. Patent No. 6,616,945 B1.

FI973151 corresponds to U.S. Patent Nos. 6,153,224 A, 6,521,260 B1 and U.S. Publication No. 2003/170183 A1.

Respectfully submitted,

Bυ

George R. Repper

Attorney for Applicants

Registration No. 31,414

ROTHWELL, FIGG, ERNST & MANBECK, p.c.

Suite 800, 1425 K Street, N.W.

Washington, D.C. 20005

Telephone: (202)783-6040

1	P.E MA	_		_				
	<i>o</i> \				Complete if Known			
2 9 1005 B INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/509,256			
*	TRADEL STATEME	TION DISCIENT BY APP	LOSURI	E r	Filing Date	June 14, 2005		
	STATEME	INI DI AII	LICHI		First Named Inventor	LANKINEN		
					Group Art Unit	1614		
					Examiner Name			
			_		Confirmation No.	1261		
ſ	Sheet	1	of	1	Attorney Docket Number	1300-142	-	

			FOR	EIGN PAT	ENT DOCUMENTS		
Examiner Initials*	Cite No.1	Office <sup>3</sup> Code	Foreign Patent Docur Number <sup>4</sup>	nent  Kind <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Τ <sup>6</sup>
	1	wo	95/01666	A1	Allied-Signal Inc.	01-12-1995	
	2	wo	02/00197	A1	Vectura Limited	01-03-2002	
	3	FI	105074		Leiras Oy	07-01-1999	AB
	4	FI	973151		Co Ordinated Drug Dev	09-30-1997	AB
Examiner Signature					Date Considered		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code. <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.